Triple Incretin Agonism — Retatrutide and the GLP-1 / GIP / Glucagon Evidence Base

Retatrutide is the most prominent member of a new pharmacological class — single molecules that agonise three incretin-family receptors (GLP-1, GIP, and glucagon). In published Phase II human trials retatrutide produced a mean body-weight reduction of approximately 24% at 48 weeks at the highest dose arm, exceeding the magnitude reported for tirzepatide in the SURMOUNT-1 obesity trial. This article reviews what the literature establishes, what it doesn't, and how the regulatory framing constrains how we discuss the class on PeptideStacks.

For receptor-level pharmacology see our GLP-1 / GIP / glucagon receptor mechanism map. For UK regulatory framing see the GLP-1 hub and weight-loss medicine advertising caution (UK).

Mechanism — why three receptors

The three receptor families address complementary metabolic levers:

• GLP-1 receptor agonism — slows gastric emptying, suppresses appetite via vagal and hypothalamic signalling, and augments glucose-dependent insulin secretion from pancreatic β-cells. This is the dominant clinical effect of mono-agonist GLP-1 medicines (semaglutide, liraglutide).
• GIP receptor agonism — augments postprandial insulin release and, in animal models, modulates adipocyte lipid handling. The role of GIP in obesity pharmacology was initially controversial — GIP was historically associated with obesity through its insulinotropic effect — but biased- agonism literature has rehabilitated it as a complementary lever in combined incretin therapy.
• Glucagon receptor agonism — increases hepatic glucose output and energy expenditure. This third arm distinguishes retatrutide from tirzepatide and is the proposed mechanism behind the additional weight reduction observed in trials.

Phase II trial evidence for retatrutide

The retatrutide Phase II programme (published 2023) randomised participants with obesity but without diabetes across multiple dose arms vs placebo across 48 weeks. Key reported endpoints:

• Body weight reduction: approximately −17%, −22% and −24% at the 4 mg, 8 mg and 12 mg arms respectively, vs −2% with placebo at 48 weeks.
• A parallel arm in type-2 diabetes reported substantial HbA1c reductions and weight loss, with the magnitude moderated by concurrent diabetes medication.
• Side-effect profile was dominated by GI symptoms (nausea, vomiting, diarrhoea), consistent with the incretin class. Dose-limiting tolerability was the primary constraint on titration speed.

The trial design used step-up dose escalation to manage GI tolerance — typical of incretin pharmacology. Phase III obesity and diabetes programmes are underway at the time of writing; no UK or US approval has been granted.

Comparative context — retatrutide vs tirzepatide

• Tirzepatide: dual GIP/GLP-1 receptor agonist; SURMOUNT-1 documented approximately 21% weight reduction at 72 weeks (15 mg arm) in adults with obesity without type-2 diabetes. UK MHRA-approved as Mounjaro.
• Retatrutide: triple GIP/GLP-1/glucagon agonist; Phase II approximately 24% at 48 weeks (12 mg arm). Not approved anywhere.

The two compounds have not been directly compared in head-to-head trials. Cross-trial comparisons are notoriously unreliable — different populations, different durations, different concomitant interventions. The published numbers above are not, in any rigorous sense, a comparison. See tirzepatide vs retatrutide — evidence comparison.

Why we don't publish a use-protocol for this class

Tirzepatide is a UK prescription-only medicine. Retatrutide is an investigational compound. Public-facing advertising of prescription-only medicines and pre-approval communication of investigational medicines are both restricted under UK law. PeptideStacks describes the trial evidence and the mechanism — it does not provide acquisition routes, dose calculators, or protocol structures for these compounds. See: prescription-only medicine advertising rules (UK), weight-loss medicine advertising caution, responsible information policy.

If a clinician considers a GLP-1 medicine appropriate for an individual patient, prescribing takes place through licensed UK pharmacy channels — not through grey-market compounded sources.

What the trial evidence doesn't establish

• Long-term durability beyond trial duration. Weight regain after cessation is a documented feature of the class; sustained-use evidence is accumulating but is constrained by trial length.
• Use in populations excluded from trials. Pregnancy, severe psychiatric history, certain cancers (boxed warning for medullary thyroid carcinoma class effect), advanced renal or hepatic impairment.
• Use as an aesthetic or recreational intervention without medical oversight. Trials studied an obesity population at clinically meaningful BMI thresholds; off-label aesthetic use is outside the studied evidence.
• Combination with unapproved peptide stacks. Trial data is for monotherapy at the studied molecule. The relevant evidence review for combinations on this site — Tirzepatide + Retatrutide + AOD-9604 — is graded conservatively for exactly this reason.

What this means for readers

The triple-agonist evidence base is, by peptide-class standards, unusually strong — but the evidence is class-specific, indication-specific, and trial-duration-specific. Online claims that outrun those constraints are the central misinformation pattern in this space. See clinical trial evidence vs online claims.